Our Companies
COMPANY PROFILE
Overcoming Unmet Needs with Innovative Immunotherapy Using Regulatory T Cells
Regcell Co., Ltd., founded in January 2016, is a university-originated biotechnology company based on the pioneering research of Dr. Shimon Sakaguchi, Nobel Laureate in Physiology or Medicine and discoverer of regulatory T (Treg) cells. The company aims to develop novel therapeutic technologies for autoimmune diseases, graft-versus-host disease, allergy, and cancer through augmenting or suppressing immune responses by targeting Treg cells.
Tregs actively maintain immune homeostasis by suppressing abnormal or excessive immune responses to self and foreign antigens.
Two projects are currently in progress. One is a Treg cell therapy by converting disease-mediating T cells into functionally stable Treg cells in vitro to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.
Tregs actively maintain immune homeostasis by suppressing abnormal or excessive immune responses to self and foreign antigens.
Two projects are currently in progress. One is a Treg cell therapy by converting disease-mediating T cells into functionally stable Treg cells in vitro to treat autoimmune and other inflammatory diseases. The other is to explore small compounds that are specifically able to deplete Treg cells in tumor tissues and thereby enhance anti-cancer immunity.
COMPANY STORY
Origin
To contribute to society by translating into practice the groundbreaking research of Dr. Shimon Sakaguchi — Professor at Kyoto University and Osaka University, Nobel Laureate in Physiology or Medicine, and discoverer of regulatory T cells (Tregs).
Strength
Our patent-protected Treg platform has generated epigenetically-reprogrammed stable and functional Treg (S/F-Epigen-Treg) which has competitive advantages compared to other Tregs in terms of stability, functionality, scalability, safety, and pathogenic antigen-specificity
S/F-Epigen-Treg cells express a high-level of Treg function-inducing molecules and achieve Treg-specific chromatin remodelling which enables functional stability
S/F-Epigen-Treg cells express a high-level of Treg function-inducing molecules and achieve Treg-specific chromatin remodelling which enables functional stability
UTEC’s value add
UTEC provides comprehensive hands-on support ranging from team building, business development, finance, and global expansion
-
Concept of S/F-Epigen-Treg therapy
-
Treg specific DNA hypomethylation
STORY LIST UTECが投資している方々やEXIT済み企業とのインタビューを掲載しています。